D-0756-2023 Class III Terminated
FDA drug recall D-0756-2023 was initiated by Amneal Pharmaceuticals Of New York, LLC on May 8, 2023 and is designated Class III. Reason for recall: Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1… The recall status is terminated (terminated Mar 21, 2024). Affected quantity: 69,239 vials.
Recall details
- Product Type
- Drugs
- Report Date
- May 31, 2023
- Initiation Date
- May 8, 2023
- Termination Date
- Mar 21, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 69,239 vials
Product description
Methylprednisolone Acetate Injectable Suspension, USP 80 mg/mL, For Intramuscular, Intrasynovial and Soft Tissue Injection Only, Not for Intravenous Use, 1 mL Single Dose Vial, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Parenteral Unit, Ahmedabad 382213, India, Amneal Pharamceuticals LLC, Bridgewater, NJ 08807, NDC 70121-1574-01.
Reason for recall
Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.
Distribution pattern
Nationwide in the USA and PR
Code information
Lot Numbers: AP220481, Exp 09/2024; AP220536A, Exp 10/2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0756-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026